Evidence map›Paper›PMID 42249083›Full record

ArticleOncogene2026

FN1

Jiangting Cheng, Wenbin Jiang, Li Liu, Ziyang Xu, Yu Dong, Youqi Qiu, Yang Qu, Yu Xia, Siyuan Dai, Jianming Guo and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiangting Cheng *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenbin Jiang *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li Liu *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ziyang Xu *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu DongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Youqi QiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yang QuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu XiaDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Siyuan DaiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. dai.siyuan@zs-hospital.sh.cn.ORCID http://orcid.org/0009-0005-8906-3773
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. guo.jianming@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-9300-8401
Jiejie XuNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7431-9063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) based therapy improved clinical outcomes in clear cell renal cell carcinoma (ccRCC), yet prognosis remains dismal in patients with advanced disease, especially those with sarcomatoid differentiation. Tumor-associated macrophages (TAMs), abundantly infiltrating in the tumor immune microenvironment (TIME), emerge as regulators of tumor evolution and immune evasion. This study aims to characterize the clinical relevance, functional phenotypes, and therapeutic vulnerability of FN1

Indexed as

Carcinoma, Renal CellFibronectinsKidney NeoplasmsMacrophagesTumor-Associated MacrophagesAnimalsCD8-Positive T-LymphocytesCell DifferentiationDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionHumansImmunotherapyPrognosisTumor MicroenvironmentFibronectinsFN1 protein, human

Identifiers

PMID42249083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.